<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ardelyx Inc — News on 6ix</title>
<link>https://6ix.com/company/ardelyx-inc</link>
<description>Latest news and press releases for Ardelyx Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ardelyx-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683547aa78dffbe2df0e37ed.webp</url>
<title>Ardelyx Inc</title>
<link>https://6ix.com/company/ardelyx-inc</link>
</image>
<item>
<title>Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-announces-abstract-exploring-ibs-c-treatment-patterns-accepted-for-poster-presentation-at-digestive-disease-week-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-announces-abstract-exploring-ibs-c-treatment-patterns-accepted-for-poster-presentation-at-digestive-disease-week-2026</guid>
<pubDate>Thu, 23 Apr 2026 12:01:00 GMT</pubDate>
<description>WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract, exploring the patient characteristics associated with irritable bowel syndrome with constipation (IBS-C) treatment patterns and their impact on gastrointestinal (GI) related healthcare resource utilization (HCRU), has been accept</description>
</item>
<item>
<title>Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-appoints-biopharmaceutical-veteran-felecia-w-ettenberg-as-chief-legal-officer</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-appoints-biopharmaceutical-veteran-felecia-w-ettenberg-as-chief-legal-officer</guid>
<pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx’s legal, compliance, regulatory, and government affairs operations</description>
</item>
<item>
<title>Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-to-report-first-quarter-2026-financial-results-on-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-to-report-first-quarter-2026-financial-results-on-april-30-2026</guid>
<pubDate>Thu, 16 Apr 2026 12:01:00 GMT</pubDate>
<description>Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, April 30, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a busines</description>
</item>
<item>
<title>Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx</title>
<link>https://6ix.com/company/ardelyx-inc/news/rajani-dinavahi-md-appointed-chief-medical-officer-of-ardelyx</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/rajani-dinavahi-md-appointed-chief-medical-officer-of-ardelyx</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization</description>
</item>
<item>
<title>Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-announces-recipients-of-the-2026-derek-forfang-patient-advocate-award-5</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-announces-recipients-of-the-2026-derek-forfang-patient-advocate-award-5</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Award recognizes leading chronic kidney disease advocates WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage</description>
</item>
<item>
<title>Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-announces-publication-of-a-review-article-demonstrating-rapid-and-meaningful-symptom-relief-with-tenapanor-in-ibs-c-25</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-announces-publication-of-a-review-article-demonstrating-rapid-and-meaningful-symptom-relief-with-tenapanor-in-ibs-c-25</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and</description>
</item>
<item>
<title>Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-and-the-lpga-announce-multi-year-partnership-to-break-stigma-around-digestive-health-issues-impacting-millions</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-and-the-lpga-announce-multi-year-partnership-to-break-stigma-around-digestive-health-issues-impacting-millions</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>First-of-its-kind partnership designed to educate and mobilize patients to imagine a healthier tomorrow DAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026</description>
</item>
<item>
<title>Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
<description>IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical</description>
</item>
<item>
<title>Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-report-full-year-and-fourth-quarter-2025-financial-results-february-19-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-report-full-year-and-fourth-quarter-2025-financial-results-february-19-2026</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical</description>
</item>
<item>
<title>Ardelyx Receives New Patent for Tenapanor</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-receives-patent-tenapanor-132900022</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-receives-patent-tenapanor-132900022</guid>
<pubDate>Tue, 03 Feb 2026 13:29:00 GMT</pubDate>
<description>New patent covers IBSRELA® and XPHOZAH® and expires in 2042WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26</description>
</item>
<item>
<title>First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA</title>
<link>https://6ix.com/company/ardelyx-inc/news/first-patient-dosed-accel-phase-132900256</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/first-patient-dosed-accel-phase-132900256</guid>
<pubDate>Wed, 28 Jan 2026 13:29:00 GMT</pubDate>
<description>WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults. ACCEL is a</description>
</item>
<item>
<title>Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-reports-preliminary-2025-revenue-133000904</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-reports-preliminary-2025-revenue-133000904</guid>
<pubDate>Thu, 08 Jan 2026 13:30:00 GMT</pubDate>
<description>Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 IBSRELA expected to achieve $410-430 million in revenue in 2026 IBSRELA revenue expected to reach $1 billion in 2029 WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, f</description>
</item>
<item>
<title>Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week</title>
<link>https://6ix.com/company/ardelyx-inc/news/real-world-evidence-studies-xphozahr-tenapanor-demonstrate-patient-satisfaction-and</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/real-world-evidence-studies-xphozahr-tenapanor-demonstrate-patient-satisfaction-and</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and</description>
</item>
<item>
<title>Ardelyx to Participate at the Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-participate-jefferies-global-healthcare-conference-london-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-participate-jefferies-global-healthcare-conference-london-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and</description>
</item>
<item>
<title>Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-president-and-chief-executive-officer-mike-raab-participate-wedbush-rewind</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-president-and-chief-executive-officer-mike-raab-participate-wedbush-rewind</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and</description>
</item>
<item>
<title>Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-reports-third-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-reports-third-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA</description>
</item>
<item>
<title>Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-presents-data-continues-support-benefits-ibsrelar-tenapanor-american-college</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-presents-data-continues-support-benefits-ibsrelar-tenapanor-american-college</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA</description>
</item>
<item>
<title>Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-announces-four-abstracts-accepted-poster-presentations-american-society</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-announces-four-abstracts-accepted-poster-presentations-american-society</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and</description>
</item>
<item>
<title>Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-report-third-quarter-2025-financial-results-october-30-2025-2025-10-13</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-report-third-quarter-2025-financial-results-october-30-2025-2025-10-13</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical</description>
</item>
<item>
<title>Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer</title>
<link>https://6ix.com/company/ardelyx-inc/news/ardelyx-appoints-experienced-finance-executive-sue-hohenleitner-chief-financial</link>
<guid isPermaLink="true">https://6ix.com/company/ardelyx-inc/news/ardelyx-appoints-experienced-finance-executive-sue-hohenleitner-chief-financial</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and</description>
</item>
</channel>
</rss>